AbbVie stock (US00287Y1091): Q1 2026 earnings highlight Skyrizi and Rinvoq as growth engines

AbbVie has reported solid Q1 2026 results with double?digit revenue growth while Humira continues to decline. Investors focus on how fast Skyrizi and Rinvoq can reshape the portfolio as management lifts near?term guidance.

AbbVie reported first-quarter 2026 results that showed the group navigating the loss of Humira exclusivity with robust growth from newer immunology drugs Skyrizi and Rinvoq. For Q1 2026, AbbVie generated revenue of about 15 billion USD, up 12.4% year over year, and delivered adjusted earnings per share of 2.65 USD, topping consensus expectations of 2.59 USD, according to data compiled by MarketBeat as of 04/29/2026. Management also updated second-quarter 2026 guidance, framing the current year as another key step in the transition toward a new generation of growth drivers.

Behind the headline numbers, the portfolio mix continued to shift. Skyrizi sales reached roughly 4.48 billion USD and Rinvoq 2.12 billion USD in Q1 2026, while Humira revenue declined further as biosimilar competition intensified, according to an overview of the quarter from Kalkine as of 05/10/2026. The strong uptake of the newer immunology therapies helped offset the erosion of the legacy blockbuster and underpinned AbbVie’s confidence in its medium-term earnings outlook.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: AbbVie Inc.
• Sector/industry: Biopharmaceuticals
• Headquarters/country: North Chicago, United States
• Core markets: United States, Europe and other international pharmaceutical markets
• Key revenue drivers: Immunology drugs including Skyrizi, Rinvoq and Humira, as well as oncology and neuroscience therapies
• Home exchange/listing venue: New York Stock Exchange (ticker: ABBV)
• Trading currency: US dollar (USD)

AbbVie Inc.: core business model

AbbVie emerged as a standalone research?driven pharmaceutical company after its spin?off from Abbott Laboratories in 2013 and has since positioned itself as a large-cap biopharma player with a focus on immunology, oncology and neuroscience. The company’s strategy centers on developing and commercializing branded prescription medicines that address chronic and often serious diseases where there is potential for differentiated efficacy and long patent protection. Within this framework, AbbVie invests heavily in late?stage clinical development, lifecycle management and label expansions to extend the commercial runway of key therapies.

For much of the past decade, Humira, an anti?TNF biologic used to treat autoimmune conditions such as rheumatoid arthritis and Crohn’s disease, served as AbbVie’s primary growth and profit engine. Humira’s success supported extensive reinvestment in research and development and underpinned shareholder returns via dividends and buybacks. However, the loss of U.S. exclusivity for Humira triggered a wave of biosimilar competition and forced the company to accelerate diversification. Management has repeatedly highlighted the need to replace Humira revenue with a broader portfolio of immunology, oncology and neuroscience assets, as reflected in strategic updates from AbbVie Investor Relations and coverage in major business media such as Ad-hoc-news as of 05/03/2024.

The new core of AbbVie’s business model revolves around a diversified group of high?value specialty medicines. Skyrizi and Rinvoq anchor the immunology franchise, while oncology contributions come from therapies such as Imbruvica, developed with Johnson & Johnson, and Venclexta. In neuroscience, AbbVie is active in migraine, movement disorders and psychiatric conditions. The company’s model relies on capturing premium pricing for innovative biologics and small?molecule drugs, building deep relationships with specialists, and demonstrating real-world value to payers who increasingly scrutinize treatment outcomes and cost-effectiveness in the United States and other key markets.

In terms of financial profile, AbbVie combines a large base of recurring revenues from chronic therapies with significant investment needs in R&D and marketing. According to MarketBeat data, the company generated annual revenue of roughly 61.16 billion USD and net income of about 4.23 billion USD in its most recently reported full year, underlining the scale of operations and the impact that portfolio shifts can have on headline earnings, as summarized by MarketBeat as of 05/15/2026. This mix of mature cash?generating products and newer launches is central to AbbVie’s ability to maintain its dividend and invest in future growth.

Main revenue and product drivers for AbbVie Inc.

Humira remains an important, though declining, contributor to AbbVie’s revenue base. Since losing U.S. exclusivity, the drug has faced rising competition from biosimilar adalimumab products, especially in the American market where payers and pharmacy benefit managers increasingly favor lower?priced alternatives. This has translated into significant year?over?year revenue declines for Humira, particularly visible in the first quarter of 2024 and subsequent periods. According to an earnings overview referenced by Ad-hoc-news as of 05/03/2024, the pressure on Humira was widely anticipated and is a key reason why AbbVie has guided investors to focus on the performance of its younger immunology drugs.

Skyrizi, a monoclonal antibody targeting IL?23, has quickly become one of AbbVie’s most important growth platforms. The drug is approved in indications such as plaque psoriasis, psoriatic arthritis and Crohn’s disease, areas characterized by high unmet medical need and the potential for long treatment durations. In Q1 2026, Skyrizi revenue reached approximately 4.48 billion USD, representing strong double?digit growth versus the prior year and confirming its role as a core driver of AbbVie’s immunology franchise, according to Kalkine as of 05/10/2026. Management has pointed to continued market share gains and new indications as levers for further expansion.

Rinvoq, an oral JAK inhibitor, complements Skyrizi in the immunology portfolio. It addresses conditions such as rheumatoid arthritis, psoriatic arthritis and atopic dermatitis, giving AbbVie a broad presence across inflammatory diseases that often require long-term management. In the first quarter of 2026, Rinvoq generated about 2.12 billion USD in revenue, also posting strong year?over?year growth, as reported by Kalkine in its review of AbbVie’s quarterly performance. Together, Skyrizi and Rinvoq are intended to replace and ultimately surpass the peak revenue once generated by Humira, forming a more diversified and resilient immunology business less dependent on a single product.

In oncology, AbbVie’s revenue mix is more complex. Imbruvica, which the company co?develops with Johnson & Johnson, has been a significant contributor in hematologic cancers but now faces intensifying competition from next?generation BTK inhibitors and evolving treatment guidelines. This has weighed on the oncology segment’s growth trajectory, even as therapies like Venclexta have provided partial offsets. AbbVie continues to invest in earlier?stage oncology assets, including antibody?drug conjugates and targeted small molecules, in an effort to reshape its cancer portfolio for the coming decade, as discussed in various company communications and summarized by Ad-hoc-news in early May 2024.

Beyond immunology and oncology, AbbVie’s neuroscience and aesthetics businesses add further diversification. The company markets therapies for migraine, movement disorders and psychiatric conditions, as well as aesthetic products acquired through the Allergan transaction, though these segments currently generate less revenue than the core immunology franchise. Together, they provide additional exposure to secular trends such as aging populations and growing demand for specialty care. For investors, tracking the relative performance of these segments versus immunology gives insight into AbbVie’s long-term balance between growth and cash generation.

On the capital allocation front, AbbVie maintains a shareholder-friendly stance with regular dividends. Market data from Google Finance indicate a quarterly dividend of 1.73 USD per share, corresponding to a dividend yield of around 3.30% based on recent trading levels, with an ex?dividend date of January 16, 2026, according to Google Finance as of 05/15/2026. This dividend policy is supported by cash flows from AbbVie’s broad portfolio and is an important element for income?oriented investors in the U.S. equity market.

Recent earnings performance and guidance

The Q1 2026 earnings release was closely watched because it offered a fresh data point on AbbVie’s ability to grow despite falling Humira sales. According to MarketBeat, the company’s 2.65 USD in adjusted EPS exceeded the consensus estimate by 0.06 USD, while revenue of 15 billion USD came in above expectations of 14.72 billion USD, as noted by MarketBeat as of 04/29/2026. Revenue growth of 12.4% year over year reflected strong contributions from Skyrizi and Rinvoq and showed that AbbVie’s newer assets can more than offset the drag from Humira, at least in the current phase of the transition.

Profitability metrics also remained solid. MarketBeat data indicate that AbbVie posted a net margin of about 5.79% in the latest quarter and a negative return on equity figure of over 500% due to balance sheet accounting effects, illustrating that headline ROE numbers must be interpreted carefully for highly leveraged or acquisition?active companies, as highlighted by MarketBeat as of 05/18/2026. Year over year, adjusted EPS increased from 2.46 USD in the same quarter of the previous year, underlining the operational leverage AbbVie can achieve when top?line growth remains robust.

Looking ahead, AbbVie issued updated guidance for the second quarter of 2026, projecting adjusted EPS in a range of 3.74 to 3.78 USD, compared with a consensus expectation of 3.74 USD, according to MarketBeat. The company also guided for Q2 2026 revenue around 16.7 billion USD, versus a consensus figure near 16.8 billion USD, signaling confidence in continued double?digit growth from key immunology products while acknowledging ongoing pressure in other areas. Investors watching the stock will likely focus on whether AbbVie can meet or exceed this guidance as new prescriptions and market share trends for Skyrizi and Rinvoq develop.

For the full year, analysts tracked by MarketBeat anticipate that AbbVie could deliver approximately 14.3 USD in EPS, illustrating expectations for a meaningful step?up from recent levels. The path to that outcome depends not only on immunology growth but also on factors such as pricing dynamics, competition in oncology and neuroscience, and macroeconomic conditions that may influence healthcare utilization and payer behavior in the United States and other markets. These uncertainties make each quarterly update a significant event for equity investors who monitor the risk?reward profile of AbbVie stock.

In the stock market, AbbVie shares have traded in a relatively wide range over the past twelve months. According to MarketBeat, the stock recently opened at about 210.54 USD, with a 52?week low of roughly 180.25 USD and a 52?week high of around 244.81 USD, as noted in a holdings update filed by Mission Wealth Management and summarized by MarketBeat as of 05/18/2026. These figures suggest that the market periodically reassesses AbbVie’s transition risks and growth prospects as new data emerge.

Why AbbVie Inc. matters for US investors

AbbVie is one of the largest biopharmaceutical companies listed on the New York Stock Exchange, making it a significant component of many U.S. equity indices and healthcare-focused portfolios. Its scale, dividend profile and exposure to specialty medicines mean that movements in AbbVie’s stock can influence sector performance and the returns of diversified U.S. mutual funds and exchange?traded funds. For U.S. investors seeking exposure to the pharmaceutical industry, AbbVie offers a combination of established cash flows and pipeline-based growth that differs from smaller biotech companies, which may be more dependent on a limited number of development-stage assets.

From a macro perspective, AbbVie’s fortunes are tightly linked to the U.S. healthcare system, where it generates a substantial portion of its revenue. Policy debates around drug pricing, reimbursement and insurance coverage can therefore have direct implications for the company’s margins and volume growth. At the same time, AbbVie’s investment decisions in R&D and manufacturing can affect employment, capital spending and innovation within the U.S. life sciences sector. This interplay between corporate strategy and public policy makes AbbVie a bellwether for broader trends in the American biopharma industry.

For income-focused U.S. investors, AbbVie’s regular dividend payments and history of dividend growth are a central consideration. The current dividend yield, while subject to market fluctuations, has often been viewed as competitive within the large-cap healthcare space, according to data from Google Finance and other market sources. At the same time, investors must weigh this income stream against risks related to patent cliffs, regulatory scrutiny and clinical trial outcomes, which can introduce volatility into the share price despite the company’s large size and diversified portfolio.

Conclusion

AbbVie’s latest quarterly figures indicate that the company is successfully leaning on Skyrizi and Rinvoq to drive growth while managing the ongoing decline of Humira in a competitive biosimilar landscape. Double?digit revenue expansion in Q1 2026 and an earnings beat versus consensus show that the transition is gaining traction, though the portfolio still faces headwinds in areas like oncology where competition and evolving treatment standards weigh on certain products. For U.S. investors, AbbVie represents a large-cap biopharma name balancing mature cash?generating assets with a pipeline of newer therapies, all under the umbrella of a sizable dividend commitment. How effectively management executes on its guidance and advances its development programs will remain central to the stock’s medium?term risk?return profile.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.